Facility expansions and over 5,800 CGT/ATMP batches manufactured underscore Cellex's strength as a trusted full-service CDMO in Europe.

RNA gene scissors (CRISPR-Cas13) are gaining significant attention as a next-generation gene therapy with fewer side effects.

Facility expansions and over 5,800 CGT/ATMP batches manufactured underscore Cellex's strength as a trusted full-service CDMO in Europe. COLOGNE, Germany, June 10, 2025 /PRNewswire/ -- Cellex ...

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support ...

The gene synthesis market has become a pivotal component of modern biotechnology, enabling rapid advancements in genomics, synthetic biology, and personalized medicine. This market is characterized by ...

Professor Won Do Heo's team in the Department of Biological Sciences develops targeted RNA modification technology, the world ...

Microglia — immune cells in the brain and spinal cord — play crucial roles in keeping the brain healthy, including helping ...

Microglia are a specialized type of immune cell that accounts for about 10% of all cells within the brain and spinal cord.

Work described in this story was made possible in part by federal funding supported by taxpayers. At Harvard Medical School, the future of efforts ...

Limited penetration depth into tumor tissues continues to hinder the development of nanotherapeutics for cancer treatment. A ...

Life sciences company Bio-Techne (NASDAQ:TECH) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 4.2% year ...

A $50 million gift to Children's Hospital of Philadelphia (CHOP) and Penn Medicine will create an ambitious joint initiative called the Lurie Autism Institute to drive discoveries with transformative ...